Pharmacogenetics and Drug Metabolism

Nature Biotechnology

Volumn 15, Issue 10, 1997, Pages 925-926

  Ball, Simon ^a   Borman, Neil ^b  

^a PFIZER INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; CLINICAL TRIAL; DRUG DESIGN; DRUG INDUSTRY; GENETIC POLYMORPHISM; GENETICS; HUMAN; INFORMATION PROCESSING; METABOLISM; PHARMACOGENETICS; PHENOTYPE;

CLINICAL TRIALS; DATA COLLECTION; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0031255198     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1097-925     Document Type: Article

References (6)

1. The genome rush of 1996 [Editorial]. Nature Biotechnology 14:1516-1518.
2. Nebert, D.W. 1997. Polymorphisms in drug-metabolizing enzymes: What is their clinical relevance and why do they exist? Am. J. Hum. Genet. 60:265-271.
3. Idle J.R. and Smith R.L 1979. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab. Rev. 9:301-317.
4. Daly, A.K. 1995. Molecular basis of polymorphic drug metabolism. J. Mol. Med. 73:539-553.
5. Ball, S.E., Scatina, J.A., Sisenwine, S.F., and Fisher, G.L. 1995. The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development. Drug Chem. Tox. 18:1-28.
6. Rendici S. and Di Carlo, F. 1997. Human cytochromes P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29:413-580.se